Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H43NO2 |
| Molecular Weight | 413.6358 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]16CC[C@@H](C)CN6
InChI
InChIKey=KWVISVAMQJWJSZ-VKROHFNGSA-N
InChI=1S/C27H43NO2/c1-16-7-12-27(28-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(29)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28-29H,6-15H2,1-4H3/t16-,17+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1
Solasodine is an aglycone of solamargine and solasonine, which are the major solasodine glycosides present in numerous species of the solanaceae family including potato, tomato or garden egg plant etc. In Phase II clinical trial was shown that solasodine glycosides exhibit anticancer activity against skin cancer. The effects of aglycone solasodine on cancer cells have also been investigated. Solasodine inhibits the growth of human colon and liver cancer cell. In addition, solasodine effectively inhibits proliferation of HER2-overexpressing breast cancer cells and inhibits invasion of human lung cancer cells. Solasodine possesses CNS activities such as antipyretic, anticonvulsant and memory enhancing effects. Also, solasodine has been found to possess diuretic, antifungal, hepatoprotective, immunomodulatory, anti-spermatogenetic and antiandrogenic effects.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24444441 |
|||
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28283413 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24444441
100 and 200mg/kg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28283413
Solasodine suppresses the invasion of A549 cells across the Matrigel-coated filter in a dose-dependent manner. Treatment with solasodine at doses of 4, 8 and 12 uM inhibit 24.5%, 43.5% and 53.6% of cell invasion, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
145043
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
442985
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
126-17-0
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
178260
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
179187
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
Solasodine
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
L40Y453Y96
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
204-774-2
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
DTXSID101030558
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
m10106
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
3538
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY | |||
|
9190
Created by
admin on Mon Mar 31 21:49:25 GMT 2025 , Edited by admin on Mon Mar 31 21:49:25 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD